References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:https://doi.org/10.3322/caac.20107
- Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. doi:https://doi.org/10.1093/annonc/mdw235
- Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am J Med. 1980;69(4):491–497. doi:https://doi.org/10.1016/s0149-2918(05)80001-3
- Jang RW, Caraiscos VB, Swami N, Banerjee S, Mak E, Kaya E, Rodin G, Bryson J, Ridley JZ, Le LW, et al. Simple prognostic model for patients with advanced cancer based on performance status. JOP. 2014;10(5):e335e41–e341. doi:https://doi.org/10.1200/JOP.2014.001457
- Wu S, Liu J, Wang X, Li M, Gan Y, Tang Y. Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies. Cancer Causes Control. 2014;25(11):1489–502. doi:https://doi.org/10.1007/s10552-014-0450-y
- Simkens LHJ, Koopman M, Mol L, Veldhuis GJ, Ten Bokkel Huinink D, Muller EW, Derleyn VA, Teerenstra S, Punt CJA. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer. 2011;47(17):2560e7–2567. doi:https://doi.org/10.1016/j.ejca.2011.06.038
- Tsang NM, Pai PC, Chuang CC, Chuang WC, Tseng CK, Chang KP, Yen TC, Lin JD, Chang JTC. Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med. 2016;5(4):665–75. doi:https://doi.org/10.1002/cam4.634
- Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll H-J, Douillard J-Y, Hurwitz H, Fuchs CS, Diaz-Rubio E, et al. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. JCO. 2016;34(2):144e50–150. doi:https://doi.org/10.1200/JCO.2015.61.6441
- Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019;8(1):86–101. doi:https://doi.org/10.21037/apm.2018.08.02
- da Cunha LP, Silveira MN, Mendes MCS, Costa FO, Macedo LT, de Siqueira NS, Carvalheira JBC. Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: A retrospective evaluation. Clin Nutr Espen. 2019;32:107–12. doi:https://doi.org/10.1016/j.clnesp.2019.04.004
- World Health Organization. Obesity: Preventing and managing the global epidemic. Report No 894, Geneva: WHO, 2000.
- Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. doi:https://doi.org/10.1056/NEJMoa0805019
- De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62. doi:https://doi.org/10.1016/S1470-2045(10)70130-3
- Irahara N, Baba Y, Nosho K, Shima K, Yan L, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010;19:157–63.
- De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812–20. doi:https://doi.org/10.1001/jama.2010.1535
- Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34. doi:https://doi.org/10.1056/NEJMoa1305275
- Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer. 2013;108(8):1757–64. doi:https://doi.org/10.1038/bjc.2013.118
- Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R. Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clin Cancer Res. 2017;23(16):4753–60. doi:https://doi.org/10.1158/1078-0432.CCR-17-0400
- Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. JCO. 2009;27(12):1948–55. doi:https://doi.org/10.1200/JCO.2008.20.2879
- Wang N, Khankari NK, Cai H, Li H-L, Yang G, Gao Y-T, Xiang Y-B, Shu X-O, Zheng W. Prediagnosis body mass index and waist-hip circumference ratio in association with colorectal cancer survival. Int J Cancer. 2017;140(2):292–301. doi:https://doi.org/10.1002/ijc.30459
- Laake I, Larsen IK, Selmer R, Thune I, Veierød MB. Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study. BMC Cancer. 2016;16:402 doi:https://doi.org/10.1186/s12885-016-2445-4
- Antoun S, Bayar MA, Dyevre V, Lanoy E, Smolenschi C, Ducreux M. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. BMC Cancer. 2019;19(1):847 doi:https://doi.org/10.1186/s12885-019-6086-2
- Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer. 2019;106:196–211. doi:https://doi.org/10.1016/j.ejca.2018.11.012
- Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CMM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr. 2009;89(4):1173–9. doi:https://doi.org/10.3945/ajcn.2008.27273
- Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, Garufi C, Iacobelli S, Tampellini M, Tumolo S, International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group, et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013;119(14):2564–73.;. doi:https://doi.org/10.1002/cncr.28072
- Kuo YH, Shi CS, Huang CY, Huang YC, Chin CC. Prognostic significance of unintentional body weight loss in colon cancer patients. Mol Clin Onc. 2018;8(4):539–43. doi:https://doi.org/10.3892/mco.2018.1582
- Cong Z, Wang D, Cao Y. The relationship between body mass index changes during chemotherapy and prognosis of patients with advanced colorectal cancer: A retrospective cohort study. Medicine (Baltimore)). 2018;97(22):e10843 doi:https://doi.org/10.1097/MD.0000000000010843
- Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75(2):188–98. doi:https://doi.org/10.1017/S0029665115004279
- Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24(5):1062–72. doi:https://doi.org/10.1158/1078-0432.CCR-17-2484
- Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: A focused review of literature. Gastroenterology Res. 2018;11(4):264–73. doi:https://doi.org/10.14740/gr1062w